Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine.
about
Classical VEGF, Notch and Ang signalling in cancer angiogenesis, alternative approaches and future directions (Review).Common therapeutic target for both cancer and obesity.Cullin-3 and its adaptor protein ANKFY1 determine the surface level of integrin β1 in endothelial cells.Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic.Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy.
P2860
Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine.
description
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
name
Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine.
@en
Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine.
@nl
type
label
Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine.
@en
Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine.
@nl
prefLabel
Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine.
@en
Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine.
@nl
P2093
P2860
P356
P1476
Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine.
@en
P2093
Carla Motta
Carmelina D Anfuso
Ferdinando Nicoletti
Gabriella Lupo
Mario Salmeri
Martina Cristaldi
Melania Olivieri
Nunzia Caporarello
Roberto Avola
Vincenzo Bramanti
P2860
P356
10.3389/FPHAR.2016.00519
P577
2016-01-01T00:00:00Z